Pancreatic Cancer Research

ResearcherAalborg University HospitalActive in the last 2 years

Morten Bækbo Ladekarl

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0182-1228; OpenAlex author ID A5051309443. Sources: OpenAlex.

Their work

Papers
20 (first author 3, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
34
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: 4 papers · 2026: 1 paper

Papers 20

  1. Characteristics, Prognosis and Reasons for Opting-Out of Treatment in Patients with Untreated Pancreatic Cancer. Co-author DOI 10.3390/curroncol33020116↗
  2. PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancr… Last author DOI 10.1007/s10637-025-01526-7↗
  3. Circulating tumour DNA (ctDNA) as a predictor of progression-free and overall survival in non-resectable pancreatic cancer: a systematic review and meta-analys… Co-author DOI 10.1016/j.jlb.2025.100441↗
  4. The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST. Co-author DOI 10.1158/1078-0432.ccr-25-0758↗
  5. ABCG2 protein expression in tumors of patients with non-resectable pancreatic cancer treated with gemcitabine and nab-paclitaxel. Last author DOI 10.3389/fonc.2025.1558184↗
  6. Pembrolizumab followed by irreversible electroporation of a liver metastasis in pancreatic cancer patients. Last author DOI 10.1016/j.isci.2024.111026↗
  7. Effect of adjuvant chemotherapy after pancreatectomy in patients with node-negative pancreatic cancer: target trial emulation. First author DOI 10.1093/bjs/znad398↗
  8. Impact on Survival of Early Versus Late Initiation of Adjuvant Chemotherapy After Pancreatic Adenocarcinoma Surgery: A Target Trial Emulation. First author DOI 10.1245/s10434-023-14497-x↗
  9. A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic c… Last author DOI 10.1186/s12885-023-11035-6↗
  10. A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic c… Last author DOI 10.21203/rs.3.rs-2955930/v1↗
  11. Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer. Co-author DOI 10.1080/0284186x.2021.2012252↗
  12. Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age: A Nationwide Real-World Danish Registry Study. Co-author DOI 10.1097/mpa.0000000000001833↗
  13. Pilot Study Experiences With Hyperpolarized [1-13 C]pyruvate MRI in Pancreatic Cancer Patients. Co-author DOI 10.1002/jmri.26888↗
  14. Acute pancreatitis as an early marker of pancreatic cancer and cancer stage, treatment, and prognosis. Co-author DOI 10.1016/j.canep.2019.101647↗
  15. Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study. Co-author DOI 10.1016/j.ejca.2020.01.015↗
  16. The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study. Co-author DOI 10.1080/0284186x.2019.1581374↗
  17. Urban versus rural residency and pancreatic cancer survival: A Danish nationwide population-based cohort study. First author DOI 10.1371/journal.pone.0202486↗
  18. Danish Pancreatic Cancer Database. Last author DOI 10.2147/clep.s99471↗
  19. Danish experiences with FOLFIRINOX as first-line therapy in patients with inoperable pancreatic cancer. Last author PMID 24814594↗
  20. [Danish Pancreatic Cancer Database]. Co-author PMID 23079448↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Frank Viborg Mortensen · 7 shared papers, 2018–2024 · strength 1.15
  2. Britta Weber · 7 shared papers, 2020–2025 · strength 1.04
  3. Louise S. Rasmussen · 7 shared papers, 2019–2025 · strength 0.98
  4. Jakob Kirkegård · 5 shared papers, 2018–2024 · strength 0.98
  5. Per Pfeiffer · 7 shared papers, 2019–2025 · strength 0.95
  6. Mogens Tornby Stender · 2 shared papers, 2024–2026 · strength 0.83
  7. Sönke Detlefsen · 6 shared papers, 2016–2024 · strength 0.77
  8. Inna Markovna Chen · 4 shared papers, 2022–2025 · strength 0.69
  9. Claus Wilki Fristrup · 7 shared papers, 2012–2022 · strength 0.65
  10. Susy Shim · 3 shared papers, 2023–2025 · strength 0.62
  11. Julia Sidenius Johansen · 3 shared papers, 2023–2025 · strength 0.55
  12. Karen‐Lise Garm Spindler · 2 shared papers, 2025 · strength 0.48
  13. Sidsel C. Lindgaard · 2 shared papers, 2025 · strength 0.48
  14. Mette M. Steiniche · 2 shared papers, 2025 · strength 0.48
  15. Carsten Palnæs Hansen · 5 shared papers, 2012–2020 · strength 0.40
  16. Susy Shim · 2 shared papers, 2023–2025 · strength 0.37
  17. Gabor Istvan Liposits · 2 shared papers, 2023 · strength 0.32
  18. Stine Brændegaard Winther · 2 shared papers, 2023 · strength 0.32
  19. Lars Henrik Jensen · 1 shared paper, 2025 · strength 0.23
  20. Michael Bau Mortensen · 3 shared papers, 2012–2020 · strength 0.22
  21. Thomas Jens Ettrich · 1 shared paper, 2025 · strength 0.21
  22. Anke Reinacher‐Schick · 1 shared paper, 2025 · strength 0.21
  23. Angelika M. R. Kestler · 1 shared paper, 2025 · strength 0.21
  24. Sture Falkmer · 2 shared papers, 2020–2021 · strength 0.21
  25. Rasmus Virenfeldt Flak · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.